Existing clinical statistics claim that a median overall survival of the is 31 months for the secondary GBM patients with IDH mutations compared to 15 months for those without mutations, whereas patients with IDH mutant anaplastic astrocytoma have 65 months of median overall survival compared to 20 months in the counterparts [12]. Here, IDH2 is linked to glioblastoma.